Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Rational design of indoleamine 2,3-dioxygenase inhibitors.

Röhrig UF, Awad L, Grosdidier A, Larrieu P, Stroobant V, Colau D, Cerundolo V, Simpson AJ, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2010 Feb 11;53(3):1172-89. doi: 10.1021/jm9014718.

PMID:
20055453
2.

Research progress of indoleamine 2,3-dioxygenase inhibitors.

Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z.

Future Med Chem. 2015;7(2):185-201. doi: 10.4155/fmc.14.151. Review.

PMID:
25686005
3.

Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors.

Lancellotti S, Novarese L, De Cristofaro R.

Curr Med Chem. 2011;18(15):2205-14. doi: 0929-8673/11 $58.00+.00. Review.

PMID:
21517759
4.

Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.

Di Pucchio T, Danese S, De Cristofaro R, Rutella S.

Expert Opin Ther Pat. 2010 Feb;20(2):229-50. doi: 10.1517/13543770903512974. Review.

PMID:
20100004
5.

Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors.

Delfourne E.

Mini Rev Med Chem. 2012 Sep 1;12(10):988-96. Review.

PMID:
22512584
6.

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).

Dolušić E, Frédérick R.

Expert Opin Ther Pat. 2013 Oct;23(10):1367-81. doi: 10.1517/13543776.2013.827662. Epub 2013 Aug 30. Review.

PMID:
23992582
7.

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.

Röhrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O.

J Med Chem. 2015 Dec 24;58(24):9421-37. doi: 10.1021/acs.jmedchem.5b00326. Epub 2015 May 26. Review.

PMID:
25970480
8.

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.

Macchiarulo A, Camaioni E, Nuti R, Pellicciari R.

Amino Acids. 2009 Jul;37(2):219-29. doi: 10.1007/s00726-008-0137-3. Epub 2008 Jul 9. Review.

PMID:
18612775
9.

Major Developments in the Design of Inhibitors along the Kynurenine Pathway.

Jacobs KR, Castellano-Gonzalez G, Guillemin GJ, Lovejoy DB.

Curr Med Chem. 2017;24(23):2471-2495. doi: 10.2174/0929867324666170502123114. Review.

10.

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH.

Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Review.

PMID:
18282734
11.

Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases.

Filippini P, Del Papa N, Sambataro D, Del Bufalo A, Locatelli F, Rutella S.

Curr Med Chem. 2012;19(31):5381-93. Review.

PMID:
22963664
12.

Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.

Rutella S, Bonanno G, De Cristofaro R.

Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):151-77. Review.

PMID:
19519465
13.

Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Zamanakou M, Germenis AE, Karanikas V.

Immunol Lett. 2007 Aug 15;111(2):69-75. Epub 2007 Jul 2. Review.

PMID:
17644189
14.

Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.

Austin CJ, Rendina LM.

Drug Discov Today. 2015 May;20(5):609-17. doi: 10.1016/j.drudis.2014.11.007. Epub 2014 Dec 3. Review.

PMID:
25478733
15.

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Katz JB, Muller AJ, Prendergast GC.

Immunol Rev. 2008 Apr;222:206-21. doi: 10.1111/j.1600-065X.2008.00610.x. Review.

PMID:
18364004
16.

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.

Selvan SR, Dowling JP, Kelly WK, Lin J.

Curr Cancer Drug Targets. 2016;16(9):755-764. Review.

PMID:
26517538
17.

Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.

Weng T, Qiu X, Wang J, Li Z, Bian J.

Eur J Med Chem. 2018 Jan 1;143:656-669. doi: 10.1016/j.ejmech.2017.11.088. Epub 2017 Dec 1. Review.

PMID:
29220788
18.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
19.

Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.

Johnson TS, Munn DH.

Immunol Invest. 2012;41(6-7):765-97. doi: 10.3109/08820139.2012.689405. Review.

PMID:
23017145
20.

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.

Brochez L, Chevolet I, Kruse V.

Eur J Cancer. 2017 May;76:167-182. doi: 10.1016/j.ejca.2017.01.011. Epub 2017 Mar 18. Review.

PMID:
28324751

Supplemental Content

Support Center